Patients became more apprehensive about being immunized against the deadly disease, after a pharmaceutical giant rebranded its drug.
Pfizer’s decision to name its COVID-19 vaccine “Cormirnaty” has done little to dispel vaccine hesitancy woes. The U.S. Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) and subsequent full approval of the jab has not helped either.
BL understands a big factor in patient reluctance is the difficulty in pronouncing the new name (koh-MEER-nah-tee). The brand name still meets the FDA’s 42-page list of requirements.
“[The vaccine is] marketed under the brand name Comirnaty, which represents a combination of the terms COVID-19, messenger ribonucleuc acid (mRNA), community, and immunity to highlight the first approval of an mRNA vaccine,” a Pfizer representative said according to Newsmax.
Comirnaty is made from the same ingredients as the EUA vaccine and administered in two doses, three weeks apart according to the FDA.
Health professionals believe confusion around the new name’s launch has only increased anxiety among those who hesitate to be vaccinated.
“[Cormirnaty] almost cancels out the fact the FDA has finally approved the vaccine,” said Robert Lahita, director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health according to the publication.
Lahita, who authored the upcoming “Immunity Strong” book, believes the brand name will even confuse those who have already decided to take the jab.
“It is going to take the removal of hesitancy that FDA approval was supposed to bring, and squirt hesitancy into the brains of those who were just about on the doorstep of having their injections.” he said.
Moderna is widely expected to market a new brand name for its COVID-19 vaccine after securing full FDA approval.
The European Medicines Association previously authorized the Brand Institute’s Spikevax vaccine.
Other proposed names include Wuhan Vax and Wuhan Corona MVax, which are tied to the location where the virus is thought to have originated from. These were “abandoned” in previous patent submissions.